JP2011162558A5 - - Google Patents

Download PDF

Info

Publication number
JP2011162558A5
JP2011162558A5 JP2011110047A JP2011110047A JP2011162558A5 JP 2011162558 A5 JP2011162558 A5 JP 2011162558A5 JP 2011110047 A JP2011110047 A JP 2011110047A JP 2011110047 A JP2011110047 A JP 2011110047A JP 2011162558 A5 JP2011162558 A5 JP 2011162558A5
Authority
JP
Japan
Prior art keywords
tissue
galnac4st
c6st
test compound
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011110047A
Other languages
English (en)
Japanese (ja)
Other versions
JP5481426B2 (ja
JP2011162558A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2011110047A priority Critical patent/JP5481426B2/ja
Priority claimed from JP2011110047A external-priority patent/JP5481426B2/ja
Publication of JP2011162558A publication Critical patent/JP2011162558A/ja
Publication of JP2011162558A5 publication Critical patent/JP2011162558A5/ja
Application granted granted Critical
Publication of JP5481426B2 publication Critical patent/JP5481426B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011110047A 2007-12-27 2011-05-17 糖鎖関連遺伝子、およびその利用 Active JP5481426B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011110047A JP5481426B2 (ja) 2007-12-27 2011-05-17 糖鎖関連遺伝子、およびその利用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007336518 2007-12-27
JP2007336518 2007-12-27
JP2011110047A JP5481426B2 (ja) 2007-12-27 2011-05-17 糖鎖関連遺伝子、およびその利用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010173610A Division JP4751956B2 (ja) 2007-12-27 2010-08-02 糖鎖関連遺伝子、およびその利用

Publications (3)

Publication Number Publication Date
JP2011162558A JP2011162558A (ja) 2011-08-25
JP2011162558A5 true JP2011162558A5 (enExample) 2013-02-14
JP5481426B2 JP5481426B2 (ja) 2014-04-23

Family

ID=40823968

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009547912A Active JP4585611B2 (ja) 2007-12-27 2008-12-26 糖鎖関連遺伝子、およびその利用
JP2010173610A Active JP4751956B2 (ja) 2007-12-27 2010-08-02 糖鎖関連遺伝子、およびその利用
JP2011110047A Active JP5481426B2 (ja) 2007-12-27 2011-05-17 糖鎖関連遺伝子、およびその利用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009547912A Active JP4585611B2 (ja) 2007-12-27 2008-12-26 糖鎖関連遺伝子、およびその利用
JP2010173610A Active JP4751956B2 (ja) 2007-12-27 2010-08-02 糖鎖関連遺伝子、およびその利用

Country Status (7)

Country Link
US (6) US20110027248A1 (enExample)
EP (4) EP3360556B1 (enExample)
JP (3) JP4585611B2 (enExample)
KR (6) KR102244872B1 (enExample)
CN (2) CN101965196A (enExample)
SG (2) SG10201402793PA (enExample)
WO (1) WO2009084232A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100329993A1 (en) * 2007-06-29 2010-12-30 Hiroyuki Yoneyama Method of fixing and expressing physiologically active substance
KR20120039742A (ko) * 2009-07-31 2012-04-25 가부시끼가이샤 스텔릭 사이세이 이카가꾸 겐뀨쇼 지방성 간염-간암 모델 동물
AU2012337691B2 (en) 2011-11-18 2017-10-12 Nitto Denko Corporation Intestinal fibrosis treatment agent
EP3121279A1 (en) * 2012-07-17 2017-01-25 Stelic Institute&Co. Mucosal healing promoter
CA2921162A1 (en) * 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
JP6302183B2 (ja) * 2013-07-12 2018-03-28 株式会社エンザミン研究所 アディポサイトカイン産生バランス調整剤及び脂肪組織の炎症・酸化ストレス抑制剤並びに脂肪組織のマクロファージ浸潤抑制剤
CA2977271A1 (en) 2015-03-02 2016-09-09 Synthetic Genomics, Inc. Regulatory elements from labyrinthulomycetes microorganisms
EP3372234B1 (en) 2015-11-04 2021-09-29 Stelic Institute & Co., Inc. Complex comprising rnai molecule and n-acetylated chitosan
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3552632B1 (en) 2016-12-07 2023-07-12 Stelic Institute & Co., Inc. Medicinal composition for treating and preventing inflammatory bowel disease
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
WO2019173226A1 (en) * 2018-03-05 2019-09-12 Synthetic Genomics, Inc. Organisms and methods for producing glycomolecules with low sulfation
CN109897812B (zh) * 2019-03-19 2021-09-03 江南大学 一种表达软骨素4-硫酸转移酶基因的重组菌及其应用
EP3967313A4 (en) * 2019-05-08 2022-11-16 TME Therapeutics Inc. MEDICATIONS FOR DECREASING ESOPHAGUS STRICTTURE
CN116254296A (zh) * 2023-03-27 2023-06-13 中国科学院微生物研究所 利用昆虫细胞杆状病毒表达系统表达硫酸软骨素修饰酶的方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4571242B2 (ja) * 1996-07-24 2010-10-27 生化学工業株式会社 ヒト由来のグリコサミノグリカンスルホトランスフェラーゼのポリペプチド及びそれをコードするｄｎａ
WO1998046258A2 (en) * 1997-04-11 1998-10-22 Beth Israel Deaconess Medical Center, Inc. Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions
JP2004504262A (ja) * 1999-12-02 2004-02-12 アイベックス　テクノロジーズ，　インコーポレイテッド 線維芽細胞の増殖の弱毒化
EP1839671A3 (en) * 1999-12-02 2007-10-31 BioMarin Pharmaceutical Inc. Attenuation of fibroblast proliferation
US6713274B2 (en) * 2002-05-13 2004-03-30 The Regents Of The University Of California Method for identifying modulators of sulfotransferase activity
AU2003252593A1 (en) * 2002-07-10 2004-02-02 Seikagaku Corporation Sulfotransferase inhibitors
PL1734970T3 (pl) * 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
WO2007049361A1 (ja) * 2005-10-27 2007-05-03 Stelic Corp. 肝線維化抑制剤
JP4147264B2 (ja) * 2006-09-08 2008-09-10 株式会社ステリック再生医科学研究所 神経線維性変性抑制剤
JP2009286695A (ja) * 2006-09-08 2009-12-10 Stelic Institute Of Regenerative Medicine 眼線維性血管新生抑制剤
US20100329993A1 (en) * 2007-06-29 2010-12-30 Hiroyuki Yoneyama Method of fixing and expressing physiologically active substance

Similar Documents

Publication Publication Date Title
JP2011037847A5 (enExample)
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
AU2018260825A1 (en) Compositions and Methods for Lowering Levels of High-Sensitivity (hs-CRP) in a Subject
BR112014023898A2 (pt) moléculas de ácido nucleico artificiais compreendendo 5''utr top
WO2016176690A3 (en) Gene therapy for autosomal dominant diseases
HK1223795A1 (zh) 拉喹莫德响应性的基因表达生物标志物
JP2012050449A5 (enExample)
EA202091568A1 (ru) Ингибиторы глюкозилцерамид-синтазы
EP2760371A4 (en) VENTRICULAR TRANSCATHETER RECONSTRUCTION STRUCTURES, METHODS AND SYSTEMS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER SUFFERING
BR112014015202A8 (pt) processo para a melhor separação de uma solução orgânica hidrófoba de um meio de cultura aquoso
WO2011156734A3 (en) Method of characterizing vascular diseases
WO2015048793A3 (en) Nucleic acid biomarker and use thereof
JP2009178558A5 (enExample)
WO2010019914A3 (en) Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
JP2016528914A5 (enExample)
NZ624708A (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
JP2013527772A5 (enExample)
PH12014502282A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
WO2013003899A8 (en) Methods of treating or preventing rheumatic disease
HK1206791A1 (en) Means and methods for response prediction of hepatitis b treatment
TN2012000607A1 (en) Method for predicting a therapy response in subjects with multiple sclerosis
RU2009145864A (ru) Способ прогнозирования дизадаптации сердечной деятельности у детей, перенесших кардиохирургическую коррекцию врожденного порока сердца
PH12019500738A1 (en) Methods of preserving the biological activity of ribonucleic acids
RU2017139718A (ru) Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток
刘旭 et al. The comparison of the serum homocysteine, uric acid and C-reactive protein levels in patients with Alzheimer's disease and vascular dementia